Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

globus medical inc. - GMED

GMED

Close Chg Chg %
72.41 -14.18 -19.58%

Open Market

58.24

-14.18 (19.58%)

Volume: 1.03M

Last Updated:

May 9, 2025, 9:40 AM EDT

Trade Now

Company Overview: globus medical inc. - GMED

GMED Key Data

Open

$60.97

 Day Range

57.15 - 60.97

52 Week Range

60.85 - 94.93

 Market Cap

$9.68B

Shares Outstanding

135.35M

 Public Float

111.93M

Beta

1.33

 Rev. Per Employee

N/A

P/E Ratio

94.28

 EPS

$0.76

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

1.06M

  

GMED Performance

1 Week
 
 0.76%
 
1 Month
 
 -0.18%
 
3 Months
 
 -17.30%
 
1 Year
 
 11.96%
 
5 Years
 
 46.35%
 

GMED Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 17
Full Ratings ➔

About globus medical inc. - GMED

Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul, David D. Davidar and Andrew Iott in March 2003 and is headquartered in Audubon, PA.

GMED At a Glance

Globus Medical, Inc.
2560 General Armistead Avenue
Audubon, Pennsylvania 19403-5214
Phone 1-610-930-1800 Revenue 2.52B
Industry Medical Specialties Net Income 102.98M
Sector Health Technology 2024 Sales Growth 60.624%
Fiscal Year-end 12 / 2025 Employees 5,300
View SEC Filings

GMED Valuation

P/E Current 94.284
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 110.723
Price to Sales Ratio 4.526
Price to Book Ratio 2.721
Price to Cash Flow Ratio 21.901
Enterprise Value to EBITDA 22.721
Enterprise Value to Sales 4.386
Total Debt to Enterprise Value 0.049

GMED Efficiency

Revenue/Employee 475,350.00
Income Per Employee 19,430.943
Receivables Turnover 4.356
Total Asset Turnover 0.487

GMED Liquidity

Current Ratio 2.544
Quick Ratio 1.774
Cash Ratio 1.04

GMED Profitability

Gross Margin 54.161
Operating Margin 9.221
Pretax Margin 4.792
Net Margin 4.088
Return on Assets 1.992
Return on Equity 2.519
Return on Total Capital 2.184
Return on Invested Capital 2.349

GMED Capital Structure

Total Debt to Total Equity 12.872
Total Debt to Total Capital 11.404
Total Debt to Total Assets 10.239
Long-Term Debt to Equity 2.008
Long-Term Debt to Total Capital 1.779
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Globus Medical Inc. - GMED

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
958.10M 1.02B 1.57B 2.52B
Sales Growth
+21.43% +6.76% +53.34% +60.62%
Cost of Goods Sold (COGS) incl D&A
257.75M 281.46M 599.21M 1.15B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
69.87M 68.25M 144.73M 254.02M
Depreciation
51.34M 50.52M 93.70M 134.65M
Amortization of Intangibles
18.53M 17.73M 51.03M 119.37M
COGS Growth
+10.01% +9.20% +112.89% +92.73%
Gross Income
700.35M 741.38M 969.27M 1.36B
Gross Income Growth
+26.25% +5.86% +30.74% +40.78%
Gross Profit Margin
+73.10% +72.48% +61.80% +54.16%
2021 2022 2023 2024 5-year trend
SG&A Expense
471.18M 504.98M 767.42M 1.13B
Research & Development
63.03M 72.86M 124.01M 151.14M
Other SG&A
408.15M 432.12M 643.41M 981.05M
SGA Growth
+13.58% +7.17% +51.97% +47.53%
Other Operating Expense
- - - -
-
Unusual Expense
57.22M 8.45M 68.71M 66.32M
EBIT after Unusual Expense
171.95M 227.95M 133.14M 165.99M
Non Operating Income/Expense
8.45M 15.07M 32.25M (41.08M)
Non-Operating Interest Income
- 9.30M 14.23M 20.13M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 4.19M
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - 4.19M
-
Interest Capitalized
- - - -
-
Pretax Income
180.41M 243.02M 165.39M 120.72M
Pretax Income Growth
+43.30% +34.71% -31.94% -27.01%
Pretax Margin
+18.83% +23.76% +10.54% +4.79%
Income Tax
31.22M 52.85M 42.52M 17.74M
Income Tax - Current - Domestic
45.12M 73.33M 96.69M 138.42M
Income Tax - Current - Foreign
3.74M 1.84M 4.08M 13.36M
Income Tax - Deferred - Domestic
(15.80M) (19.57M) (52.64M) (117.97M)
Income Tax - Deferred - Foreign
(1.85M) (2.76M) (5.61M) (16.07M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
149.19M 190.17M 122.87M 102.98M
Minority Interest Expense
- - - -
-
Net Income
149.19M 190.17M 122.87M 102.98M
Net Income Growth
+45.86% +27.47% -35.39% -16.19%
Net Margin Growth
+15.57% +18.59% +7.83% +4.09%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
149.19M 190.17M 122.87M 102.98M
Preferred Dividends
- - - -
-
Net Income Available to Common
149.19M 190.17M 122.87M 102.98M
EPS (Basic)
1.481 1.8928 1.0865 0.7588
EPS (Basic) Growth
+42.73% +27.81% -42.60% -30.16%
Basic Shares Outstanding
100.73M 100.47M 113.09M 135.73M
EPS (Diluted)
1.4398 1.8527 1.0719 0.747
EPS (Diluted) Growth
+42.13% +28.68% -42.14% -30.31%
Diluted Shares Outstanding
103.62M 102.64M 114.63M 137.86M
EBITDA
299.04M 304.65M 346.58M 486.34M
EBITDA Growth
+47.48% +1.88% +13.76% +40.32%
EBITDA Margin
+31.21% +29.78% +22.10% +19.30%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 97.462
Number of Ratings 17 Current Quarters Estimate 0.844
FY Report Date 06 / 2025 Current Year's Estimate 3.438
Last Quarter’s Earnings 0.75 Median PE on CY Estimate N/A
Year Ago Earnings 3.14 Next Fiscal Year Estimate 3.92
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 15 15 13 15
Mean Estimate 0.84 0.85 3.44 3.92
High Estimates 0.91 0.90 3.50 4.29
Low Estimate 0.72 0.77 3.35 3.68
Coefficient of Variance 6.14 4.84 1.22 3.20

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 11 11 10
OVERWEIGHT 2 2 1
HOLD 4 4 5
UNDERWEIGHT 0 0 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Globus Medical Inc. - GMED

Date Name Shares Transaction Value
Nov 26, 2024 Daniel T. Lemaitre Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85.02 per share 0.00
Nov 26, 2024 Daniel T. Scavilla President, CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 26, 2024 Daniel T. Scavilla President, CEO; Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 26, 2024 Daniel T. Scavilla President, CEO; Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85 per share 0.00
Nov 26, 2024 Daniel T. Scavilla President, CEO; Director 130,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $43.58 per share 5,665,400.00
Nov 26, 2024 Daniel T. Scavilla President, CEO; Director 50,000 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $43.77 per share 2,188,500.00
Nov 26, 2024 Daniel T. Lemaitre Director 625 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 26, 2024 Daniel T. Lemaitre Director 1,722 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Nov 26, 2024 Daniel T. Lemaitre Director 1,097 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $65.05 per share 71,359.85
Nov 26, 2024 Daniel T. Lemaitre Director N/A Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85 per share 0.00
Nov 26, 2024 Daniel T. Lemaitre Director 13,278 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $65.05 per share 863,733.90
Nov 26, 2024 David D. Davidar Director 165,967 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85 per share 14,107,195.00
Nov 26, 2024 David D. Davidar Director 516,275 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85 per share 43,883,375.00
Nov 26, 2024 David D. Davidar Director 172,713 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85 per share 14,680,605.00
Nov 26, 2024 David D. Davidar Director 523,041 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $85 per share 44,458,485.00
Jul 16, 2024 Leslie V. Norwalk Director 16,419 Open market or private sale of non-derivative or derivative security Non-derivative transaction at $70 per share 1,149,330.00
May 15, 2024 Daniel T. Lemaitre Director N/A Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00

Globus Medical Inc. in the News